There is something of a controversy at the moment over the decision of the FDA not to recognise Oblimersen (BCL2 antisense) for the treatment of CLL. Spare a moment for Zheng Xiaoyu, once head of the Chinese FDA.
On July 10th this year Zheng was executed for taking bribes worth $840,000 from eight Chinese pharmaceutical companies in return for illegally approving their products. (There were 1010 recorded executions in China in 2002 according to Amnesty International).
Among the drugs approved by Zheng's regime were Gendicine, a recombinant human adenovirus type 5 which aims to introduce wild type p53 gene into cells with mutant p53. It was an immune reaction to adenovirus that killed Jesse Gelsinger the first person in the world to die from gene therapy.
This is not to say that the Chinese virus killed Jesse, but it suggests that the Chinese FDA might have been cavalier in licensing their product. Gendicine is analogous to the US drug Advexin, which is still in clinical trials and is not yet licensed. It may be that China, by applying less stringent criteria for licensing than the US, has leap-frogged America in the field of gene therapy. I suppose the lesson is if you are going to take risks with people's health don't take bribes for doing it.